tbuckley/cabot-search huggingface dataset:
Competitive Awards Under the Fulbright Act 1953–54
Journal: JNCI Journal of the National Cancer Institute (1952)

Competitive Awards Under the Fulbright Act 1953–54 Get access JNCI: Journal of the National Cancer Institute, Volume 13, Issue 1, August 1952, Page 279, https://doi.org/10.1093/jnci/13.1.279-a Published: 01 August 1952
Syphilis
Authors: Robert F. Tilley
Journal: New England Journal of Medicine (1955)

TherapyThe worth of penicillin as an agent for the management of all types of syphilis has been established. The end results of intensive follow-up studies have confirmed the initial impressions of the conservative syphilologists. Penicillin is the drug of choice because of its ease of administration and nontoxicity. Retreatment should be instituted in the face of an obvious clinical relapse or progression. Serorelapse should also be considered an indication for further therapy. These failures can only be determined by the proper observation of the patient. Once treatment is instituted the patient must be followed and all the persons known . . .
Tinnitus
Authors: Alan H. Lockwood, Richard J. Salvi, Robert F. Burkard
Journal: New England Journal of Medicine (2002)

Tinnitus is a common but poorly understood disorder that has a strong association with aging. This review explains how to differentiate subjective from objective tinnitus. Although tinnitus is often associated with hearing loss, in many cases the origin may be central. Multiple treatment options may help in the management of this chronic condition.
Gene-toxicant link to Parkinson's disease
Authors: Brian Balin, Alan Hudson
Journal: Environmental Health Perspectives (1999)

led what may prove to be a huge step forwarding in understanding Alzheimer's.Says Balin, "We don't have a definite cause yet, but we definitely have a potential cause or risk fac- tor for the disease."C. pneumoniae is the cousin of C. tra- chomatis, which causes both the sexually transmitted infection commonly known as chlamydia and trachoma, a form of blindness.C. pneumoniae is a pervasive bacteri- um, appearing in 40-70% of adults.Unlike most other bacteria, C. pneumoniae can only live inside a cell and draws its energy from the cell's supply of adenosine triphosphate.The bacterium is spread through sneezing and coughing, and causes diseases such as sinusitis and bronchitis.In studying the relationship between C. pneumoniae and lateonset Alzheimer's, Balin and Hudson used postmortem samples from various regions of the brains of patients both with and without Alzheimer's.From each sample, the scientists prepared samples of nucleic acid, which were screened by polymerase chain reaction assay for the presence of two C. pneumoniae marker genes.Analyses showed that sam- ples from 17 of the 19 brains with Alzheimer's tested positive for the bacteria, while only 1 of 19 brain samples without Alzheimer's tested positive.
Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study.
Authors: Michael Szarek, Michael N. Needle, Brian I. Rini, Sumanta K. Pal, David F. McDermott, Michael B. Atkins, Thomas E. Hutson, Bernard Escudier
Journal: Journal of Clinical Oncology (2021)

298 Background: In the randomized phase III study TIVO-3, the VEGFR-TKI tivozanib (TIVO) increased progression-free survival with better tolerability but no difference in overall survival (OS) relative to sorafenib (SORA) as third- or fourth-line therapy in patients with metastatic RCC. These results provide motivation to apply quality-adjusted time without symptoms of disease and toxicity (Q-TWiST) methods to quantify the net health benefits of TIVO, in the presence of similar survival, when compared to SORA. Methods: In application of Q-TWiST, patient-level OS was subdivided into three mutually exclusive states: time with toxicity (TOX), time without symptoms and toxicity (TWiST), and time after progression/relapse (REL). Mean Q-TWiST was calculated by applying utility coefficients of 0.5, 1.0, and 0.5 to the restricted mean (max 36 months follow-up) health states of TOX, TWiST, and REL, respectively; 95% CIs for the means and mean differences were estimated by bootstrap distributions. Relative Q-TWiST gain was defined as the mean absolute Q-TWiST difference divided by the SORA mean OS. Results: Mean TWiST was significantly longer for TIVO than for SORA (10.30 months v.5.35 months; Table). Mean REL time was significantly shorter for TIVO, with no difference in mean TOX time. Mean Q-TWiST was 15.04 and 12.78 months for TIVO and SORA, respectively, a statistically significant difference (p=0.0493). The relative gain for TIVO was 11.2%. Clinical trial information: NCT02627963 . Values in table are mean (95% CI) in months or p-value for difference in treatment group means. Conclusions: The difference in Q-TWiST in TIVO-3 was primarily driven by benefits of TIVO in TWiST, partially offset by superiority of SORA in REL time. As a third- or fourth-line treatment for RCC, TIVO significantly increased Q-TWiST relative to SORA, primarily through an increase in TWiST, which is generally considered to be the state with highest utility to patients. Consequently, Q-TWiST may be considered an alternative patient-centered measure of benefit of TIVO in these settings. [Table: see text]
Topical oropharyngeal anesthesia in patients with obstructive sleep apnea.
Authors: P C Deegan, E Mulloy, W T McNicholas
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Topical oropharyngeal anesthesia (TOPA) increases obstructive sleep apnea (OSA) frequency in both normal subjects and loud snorers. The effects of TOPA in established OSA were assessed in six male patients with a mean age (+/- SEM) of 50 +/- 5.3 yr. Following an acclimatization night, each subject underwent two overnight sleep studies, randomly assigned to TOPA (10% lidocaine spray and 0.25% bupivocaine gargle) and control (C) (saline placebo). Patients demonstrated sleep efficiencies of 93 +/- 2.9% (mean +/- SEM) during C and 88 +/- 2.9% during TOPA. Overall apnea-hypopnea (AH) frequency, using inductance plethysmography, showed little change: 21.2 +/- 3.6 on C versus 25.1 +/- 3.5 events/h on TOPA nights (p = 0.12). There was no significant increase in AH duration with TOPA, and oxygen desaturation (> or = 4%) frequency was similar: 21.1 +/- 3.9 per hour during TOPA versus 23.6 +/- 5.9 during C. However, obstructive AHs showed a change in thoracoabdominal motion from C to TOPA nights, with an increase in events with abdominal paradox from 3.1 +/- 1.1 to 10.3 +/- 3.1 per hour (p = 0.03), and a reduction in events with ribcage paradox from 13.1 +/- 1.6 to 8.2 +/- 2.4 per hour (p = 0.08). Central and mixed AHs demonstrated similar frequencies on both nights. These data support an impairment of upper airway (UA) protective reflexes among patients with OSA.
Genetic and Cellular Analysis of Behavior in C. elegans
Authors: B. Cornelia I.
Journal: Annual Review of Neuroscience (1993)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
Masthead
Authors: Paul Berk, New York, Andres Blei, Herbert Bonkovsky, Adrian Di Bisceglie, Maryland Bethesda, A Michael, New Gerber, Robert Glickman, Ann Boston, Maryland Hubbard, Sun Jones, Willis Francisco, Esteban Dallas, Maryland Baltimore, Nicola Tavoloni, Allan Wolkoff, Raymond Koff, Jorge Gumucio, Ann Arbor, Irwin Arias, Michelle Britton, Kerry Carlyle, Esteban Mezey, John Gollan, Eugene Schiff, Florida Miami, Jay Hoofnagle, Roger Lester, Little Rock, Michael Sorrell, John Vierling, Los Angeles, Vinod Rustgi, Virginia Fairfm, New Gaines, William York, Texas Dallas, Jon Councillors, Nebraska Omaha, Sun Montgomery Bissell, David Francisco, Anthony Crabb, Scott Cleveland, Sun Friedman, Nicholas Francisco, Rochester Larusso, Steven Schenker
Journal: Hepatology (1993)
BOOK REVIEWS
Authors: E. L. WYNDER
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article BOOK REVIEWS Get access Primary Prevention of Cancer, Volume 19, Monograph series of the European Organization for Research and Treatment of Cancer. W. J. Eylenbosch, A.-M. Depoorter, N. van Larebeke, eds. New York, NY: Raven Press, 1988, 383. pp. $69.00. ERNST L. WYNDER ERNST L. WYNDER American Health Foundation320 East 43rd Street, New York, NY 10017 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 18, 16 November 1988, Page 1498, https://doi.org/10.1093/jnci/80.18.1498 Published: 16 November 1988
PRACTICAL POINTS CONCERNING MALARIA.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical roads lead to new hospital in Rome
Authors: M. F. Goldsmith
Journal: JAMA (1991)

ON THE OUTSKIRTS of Rome, three starkly modern buildings house a comprehensive medical facility whose concept and operation contrast as much with the usual public-sector Italian health care as the sleek architecture does with the antiquities of the city center. Rome American Hospital was opened as a profit-making venture by a group of Italian investors in May 1990, because of what Charles W. Neumann, an American and its chief executive officer, calls "the pressing demand for private health care in Italy." "It's ironic, isn't it?" Neumann asks. "Every European country that has a very large national health care commitment is looking for ways to reduce that commitment or shift it a bit more to the private sector. And in the United States, you're looking at just the opposite." Neumann was managing director of the European division of the Hospital Corporation of America Inc, which planned the Rome facility then turned
MISCELLANY.
Authors: J. J. Kinyoun
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cholinesterase Demonstration of Dermal Nerve Endings in Patients with Impaired Sensation: A Clinical and Pathologic Study of 41 Patients and 37 Control Subjects
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chest Measurement as a Gage of Body Weight.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Farsightedness
Authors: Christopher Krogh
Journal: JAMA (1985)

<h3>To the Editor.—</h3> Having just returned from a medical conference I particularly appreciated Dr Hammerschmidt's fine article<sup>1</sup>and wish that more of the speakers had read it. I have an even simpler rule for preparing slides: if you can hold a slide up a foot in front of your eyes and clearly read its contents, you can be certain your entire audience will be able to read it when it is projected in almost all normal circumstances. I have used this rule for years and have never had a complaint about an unreadable slide.
NEDD8 specific protease 1 (NEDP1) as a tumor suppressor in hepatocellular carcinoma
Authors: Marina Serrano-Macia, Aymeric Bailly, Aurelien Perrin, Maghames Chantal, Orsolya Leidecker, Helene Trauchessec, Naroa Goikoetxea, Rubén Rodríguez Agudo, Sofia Lachiondo-Ortega, Anton Gartner, Teresa Cardoso Delgado, Dimitris Xirodimas, Mariá Luz Martińez-Chantar
Journal: Journal of Hepatology (2020)
The Scientific Program
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identification of Ultimate DNA Damaging Oxygen Species
Authors: Bernd Epe, Jutta Hegler, Dieter Wild
Journal: Environmental Health Perspectives (1990)

DNA damage induced by various reactive oxygen species can be characterized using a set of repair endonucleases with defined substrate specificities. DNA damage profiles thus obtained in a cell-free system can be compared with those observed in cellular DNA. Using this approach, we have demonstrated that an illumination of Salmonella typhimurium cells with visible light in the presence of methylene blue gives rise to a DNA damage profile very similar to that of singlet oxygen in a cell-free system. Therefore, the genotoxicity observed under these conditions most probably is attributable to the direct action of this species. The damage consists mainly of base modifications that are subject to repair by uvrABC-independent pathways. Revertant frequencies observed in parallel in the strains TA100 and TA2638 indicate a pronounced mutagenicity of the lesions induced. Exposure of Salmonella typhimurium to tert-butylhydroperoxide gives rise to another form of damage profile that is also different from that produced by hydroxyl radicals in a cell-free system. However, the latter dissimilarity does not exclude hydroxyl radicals as ultimate reactive species, as a very rapid repair of the induced base modifications is observed, which might have distorted the damage profile despite immediate work up.
Tumor Registry for Cases of Immunodeficiency Disease and Cancer
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Tumor Registry for Cases of Immunodeficiency Disease and Cancer Get access JNCI: Journal of the National Cancer Institute, Volume 56, Issue 6, June 1976, Page 1285, https://doi.org/10.1093/jnci/56.6.1285-a Published: 01 June 1976
Reply
Authors: J. N.L. Schouten, H. L.A. Janssen
Journal: Hepatology (2010)

We would like to thank Goel et al. for their reply to our review of idiopathic noncirrhotic portal hypertension (INCPH).1, 2 The authors studied the prevalence of INCPH among all new portal hypertension patients from July 2009 until July 2010. Eventually, 17 (39%) patients were diagnosed with INCPH. The authors described the morphological features observed in liver specimens from these 17 INCPH patients. Interestingly, neither the presence of nodular regenerative hyperplasia nor obliteration of portal venules (phlebosclerosis)—both the most frequently observed morphological features in liver specimens of Western INCPH patients—were found.3, 4 The apparent absence of these features in Indian INCPH patients could imply differences in pathophysiological mechanisms between patients from different continents. As reported by Goel et al., liver biopsy is mandatory in the diagnosis of INCPH. Its main role is the exclusion of liver cirrhosis, which may be very difficult to discern by radiological examinations only. In addition, the diagnosis of INCPH can be suggested or supported by the presence of morphological features such as nodular regenerative hyperplasia, phlebosclerosis, increased number of portal vascular channels, paraportal shunt vessels, and sinusoidal dilatation. However, one must take into account that these features can also be observed in patients without clinical signs of portal hypertension. J.N.L. Schouten M.D.*, H.L.A. Janssen Ph.D.*, * Department of Gastroenterology Hepatology, University Hospital Rotterdam, Rotterdam, The Netherlands.
A phase II, noncomparative, open label, multicentre, study of AZD9291 in patients with locally advanced or metastatic EGFR mutated “T790M undetectable or unknown” non-small cell lung cancer (stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study).
Authors: Hector J. Soto Parra, Laura Noto, Domenico Galetta, Francesco Ferraú, Vittorio Gebbia, Pierfrancesco Tassone, Francesco Verderame, Marco M. Aiello, Fiorenza Latteri, Silvia Novello
Journal: Journal of Clinical Oncology (2017)

TPS9107 Background: Osimertinib (OSI), is an oral, potent, irreversible inhibitor of both epidermal growth factor receptor (EGFR) sensitizing and resistance mutations (T790M) indicated for the treatment of pts with advanced EGFR T790M mutation-positive NSCLC. In the AURA study, OSI was associated with an ORR of 21% (13/61) among all patients with T790M negative mutation. Response rate broken down by immediate versus no immediate prior EGFR TKI was 11% (4/36 pts) versus 36% (9/25) respectively. This better activity with deferred OSI, drug able to inhibit also the EGFR sensitizing mutations, could be explained by a selection of sensitive tumor cells during chemotherapy (re-challenge strategy). Aim of the current study is prospective evaluate the efficacy of OSI in EGFR mutated, T790M “undetectable or unknown” patients as third-line therapy after a first-line EGFR TKI and a subsequent chemotherapy. Methods: OSIRIS study is a prospective single-arm, phase 2, open label, italian multicenter study. T790M “undetectable or unknown" is defined by the following conditions: inconclusive/negative tumor test result for T790M at the time of disease progression or medical inaccessible/contraindications/declined tumor biopsy or insufficient tumor tissue for testing. Pts are treated with OSI 80 mg once daily until disease progression or unacceptable toxicity. The single-arm design is appropriate, as there is no accepted standard therapy for these pts after chemotherapy. The primary endpoint is ORR according to RECIST version 1.1. The null hypothesis that the true response rate is 9% will be tested against a one-sided alternative. In the first stage, 32 pts will be accrued. If there are 3 or fewer responses in these 32 pts, the study will be stopped. Otherwise, 49 additional pts will be accrued for a total of 81. This design yields a type I error rate of 0.05 and power of 80% when the true response rate is 19%. Secondary endpoints are PFS, OS and safety. Exploratory: mutational analysis of a panel of genes involved in resistance to EGFR-TKIs is planned. Clinical trial information: 2016-002555-17.